Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05379985
Trial Phases:	Phase I Phase II	Protocol IDs:	RMC-6236-001 (primary) NCI-2022-05170
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Revolution Medicines, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05379985

Summary

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant
advanced solid tumors.

Objectives

This is a Phase 1/2, multicenter open-label study to evaluate the safety, tolerability,
pharmacokinetics (PK), and clinical activity of escalating doses of RMC-6236 in adult
patients with advanced solid tumors harboring specific RAS mutations, and to determine
the maximum tolerated dose (MTD) and/or recommended phase 2 dose [RP2D] within
investigated patient population groups. RMC-6236 is a potent, orally bioavailable
RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and
mutant variants of the canonical RAS isoforms (HRAS, NRAS, and KRAS).

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.